Adaptimmune Therapeutics annual revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Adaptimmune Therapeutics Revenue Growth & History (ADAPY)
Adaptimmune Therapeutics reported $178.0M in revenue for fiscal 2024, an increase of 195.34% from the previous fiscal year.
View full Adaptimmune Therapeutics company overviewAdaptimmune Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $178.0M | $117.8M | +195.34% |
| 2023 | 2023-12-31 | $60.3M | $33.1M | +122.05% |
| 2022 | 2022-12-31 | $27.1M | $21.0M | +341.50% |
| 2021 | 2021-12-31 | $6.1M | $2.2M | +55.36% |
| 2020 | 2020-12-31 | $4.0M | $2.8M | +252.76% |
| 2019 | 2019-12-31 | $1.1M | −$58.4M | −98.11% |
| 2018 | 2018-12-31 | $59.5M | $21.7M | +57.28% |
| 2017 | 2017-12-31 | $37.8M | $23.6M | +166.47% |
| 2016 | 2016-12-31 | $14.2M | $4.3M | +43.84% |
| 2015 | 2015-06-30 | $9.9M | $9.0M | +1096.48% |
| 2014 | 2014-06-30 | $825,000 | — | — |
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Primary source
SEC company filings
TickerStat standardizes reported company facts from SEC EDGAR. Derived growth rates use the displayed revenue values and are not company guidance or forecasts.
Review Adaptimmune Therapeutics filings at SEC.gov ↗